Brain Natriuretic Peptide Levels Predict Morbidity and Mortality in Haemodialys...

• Author(s): Matias, P ; Jorge, C ; Aires, I ; Lage, H ; Gil, C ; Gomes, F ; Arranhado, E ; Ferreira, A
• Date: 2009
• Persistent ID: http://hdl.handle.net/10400.17/1803
• Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
• Subject(s): HCC NEF; Peptídeo Natriurético Encefálico; Mortalidade; Hemodiálise
• Document Type: Article
• Language: English

Description

Background: Brain natriuretic peptide is a predictor of mortality in multiple cardiovascular diseases but its value in patients with chronic kidney disease is still a matter of debate. Patients and methods: We studied 48 haemodialysis patients with mean age 70.0±13.9 years,62.5% female, 43.8% diabetics, with a mean haemodialysis time of 38.1±29.3 months. To evaluate the role of brain natriuretic peptide as a prognostic factor in this population we performed a two-session evaluation of pre- and postmid-week haemodialysis plasma brain natriuretic peptide concentrations and correlated them with hospitalisation and overall and cardiovascular mortality over a two-year period. Results: There were no significant variations in pre– and post-haemodialysis plasma brain natriuretic peptide concentrations. Pre- and post-haemodialysis brain natriuretic peptide concentrations were significantly greater in patients who died from all causes(p=0.034 and p=0.001, respectively) and from cardiovascular causes (p=0.043 and p=0.001, respectively). Patients who were hospitalised in the two-year study period also presented greater pre- and posthaemodialysis brain natriuretic peptide concentrations(p=0.03 and p=0.036, respectively). Patients with mean brain natriuretic peptide concentrations ≥ 390 pg/mL showed a significantly lower survival at the end of the two-year study period. Conclusion: Brain natriuretic peptide was a good predictor of morbidity and mortality (overall and cardiovascular) in our population.